Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: MULTIPLE SCLEROSIS, RELAPSING-REMITTING - DRUG THERAPY , . Treffer: 13

2019

Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T; Austrian MS Treatment Registry (AMSTR) Real-life use of oral disease-modifying treatments in Austria.
Acta Neurol Scand. 2019; 140(1):32-39 Doi: 10.1111/ane.13097 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Rossi, S; Studer, V; Motta, C; Polidoro, S; Perugini, J; Macchiarulo, G; Giovannetti, AM; Pareja-Gutierrez, L; Calò, A; Colonna, I; Furlan, R; Martino, G; Centonze, D Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
Neurology. 2017; 89(13): 1338-1347. Doi: 10.1212/WNL.0000000000004411
Web of Science PubMed FullText FullText_MUG

 

2016

Sormani, MP; Gasperini, C; Romeo, M; Rio, J; Calabrese, M; Cocco, E; Enzinger, C; Fazekas, F; Filippi, M; Gallo, A; Kappos, L; Marrosu, MG; Martinelli, V; Prosperini, L; Rocca, MA; Rovira, A; Sprenger, T; Stromillo, ML; Tedeschi, G; Tintorè, M; Tortorella, C; Trojano, M; Montalban, X; Pozzilli, C; Comi, G; De Stefano, N; MAGNIMS study group Assessing response to interferon-β in a multicenter dataset of patients with MS.
Neurology. 2016; 87(2):134-140 Doi: 10.1212/WNL.0000000000002830 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Hegen, H; Millonig, A; Bertolotto, A; Comabella, M; Giovanonni, G; Guger, M; Hoelzl, M; Khalil, M; Killestein, J; Lindberg, R; Malucchi, S; Mehling, M; Montalban, X; Polman, CH; Rudzki, D; Schautzer, F; Sellebjerg, F; Sørensen, PS; Deisenhammer, F Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Mult Scler. 2014; 20(5):577-587 Doi: 10.1177/1352458513503597
Web of Science PubMed FullText FullText_MUG

 

2011

Barkhof, F; Simon, JH; Fazekas, F; Rovaris, M; Kappos, L; de Stefano, N; Polman, CH; Petkau, J; Radue, EW; Sormani, MP; Li, DK; O'Connor, P; Montalban, X; Miller, DH; Filippi, M MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.
Nat Rev Neurol. 2011; 8(1):13-21 Doi: 10.1038/nrneurol.2011.190
Web of Science PubMed FullText FullText_MUG

 

2009

Comi, G; Martinelli, V; Rodegher, M; Moiola, L; Bajenaru, O; Carra, A; Elovaara, I; Fazekas, F; Hartung, HP; Hillert, J; King, J; Komoly, S; Lubetzki, C; Montalban, X; Myhr, KM; Ravnborg, M; Rieckmann, P; Wynn, D; Young, C; Filippi, M Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Lancet. 2009; 374(9700):1503-1511 Doi: 10.1016/S0140-6736(09)61259-9
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Gneiss, C; Koudouovoh-Tripp, PM; Ropele, S; Gotwald, T; Ehling, R; Lutterotti, A; Aichner, F; Ladurner, G; Eggers, C; Schautzer, F; Künz, B; Millonig, A; Aspeck, E; Reindl, M; Berger, T; Fazekas, F; Deisenhammer, F Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Mult Scler. 2009; 15(12): 1481-1488. Doi: 10.1177/1352458509347153
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Killestein, J; Jasperse, B; Liedorp, M; Seewann, A; Polman, Ch Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies.
Mult Scler. 2009; 15(4): 525-526. Doi: 10.1177/1352458508101322
Web of Science PubMed FullText FullText_MUG

 

2008

Fazekas, F; Lublin, FD; Li, D; Freedman, MS; Hartung, HP; Rieckmann, P; Sorensen, PS; Maas-Enriquez, M; Sommerauer, B; Hanna, K Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Neurology. 2008; 71(4):265-271 Doi: 10.1212/01.wnl.0000318281.98220.6f
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Gneiss, C; Tripp, P; Reichartseder, F; Egg, R; Ehling, R; Lutterotti, A; Khalil, M; Kuenz, B; Mayringer, I; Reindl, M; Berger, T; Deisenhammer, F Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Mult Scler. 2006; 12(6):731-737 Doi: 10.1177/1352458506070941
Web of Science PubMed FullText FullText_MUG

 

2002

Fazekas, F; Ropele, S; Enzinger, C; Seifert, T; Strasser-Fuchs, S Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis.
Mult Scler. 2002; 8(6):479-484 Doi: 10.1191/1352458502ms860oa
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Neuhaus, O; Strasser-Fuchs, S; Fazekas, F; Kieseier, BC; Niederwieser, G; Hartung, HP; Archelos, JJ Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neurology. 2002; 59(7):990-997 Doi: 10.1212/WNL.59.7.990
Web of Science PubMed FullText FullText_MUG

 

Sorensen, PS; Fazekas, F; Lee, M Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
Eur J Neurol. 2002; 9(6):557-563 Doi: 10.1046%2Fj.1468-1331.2002.00501.x
Web of Science PubMed FullText FullText_MUG

 

© Med Uni Graz Impressum